Part 2: The Clinical Applications of Left Ventricular Myocardial Strain

Malcolm Anastasius; Paaladinesh Thavendiranathan; Annapoorna Kini; Edgar Argulian; Samin Sharma; Jagat Narula; Stamatios Lerakis

doi:10.1097/CRD.0000000000000560

Part 2: The Clinical Applications of Left Ventricular Myocardial Strain

Cardiol Rev. 2023 Jun 5. doi: 10.1097/CRD.0000000000000560. Online ahead of print.

Authors

Malcolm Anastasius¹, Paaladinesh Thavendiranathan², Annapoorna Kini¹, Edgar Argulian¹, Samin Sharma¹, Jagat Narula¹, Stamatios Lerakis¹

Affiliations

¹ From the Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY.
² Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.

PMID: 37273187
DOI: 10.1097/CRD.0000000000000560

Abstract

There is an increasing prevalence of cardiovascular disease and heart failure. Indices of left ventricular (LV) systolic function such as LV ejection fraction used to identify those at risk of adverse cardiac events such as heart failure may not be truly representative of LV systolic function in certain cardiac diseases. Given that LV ejection fraction reduction may represent more advanced irreversible stages of disease, measures of myocardial strain have emerged as a feasible and robust instrument for the early identification of heart disease and subtle LV systolic dysfunction. The purpose of this review was to provide an overview of emerging clinical applications of LV global longitudinal strain in valvular and cardiomyopathic diseases and coronavirus disease 2019.